SCHEMBL19441967

SCHEMBL19441967

COc1cc(OC)c(Cl)c(NC(=O)N(Cc2ccc(NC(C)=O)cc2)c2cc(Nc3ccc(N4CCN(C)CC4)cc3)ncn2)c1Cl

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 15/20 0.84
FGFR1 P11362 4/20 0.84
FGFR4 P22455 4/20 0.84
FGFR2 P21802 3/20 0.84
EGFR P00533 1/20 0.84
LCK P06239 4/20 0.66
JAK2 O60674 2/20 0.66
ABL1 P00519 2/20 0.66
INSR P06213 2/20 0.66
FYN P06241 2/20 0.66
YES1 P07947 2/20 0.66
LYN P07948 2/20 0.66
RET P07949 2/20 0.66
MET P08581 2/20 0.66
ROS1 P08922 2/20 0.66
KIT P10721 2/20 0.66
SRC P12931 2/20 0.66
BRAF P15056 2/20 0.66
PDGFRA P16234 2/20 0.66
FLT1 P17948 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19753756 0.93 FGFR3 (0.82) FGFR3FGFR1FGFR4FGFR2EGFR
SCHEMBL29363673 0.92 FGFR1 (1.00) FGFR3FGFR1FGFR4FGFR2EGFR
SCHEMBL17857056 0.92 FGFR1 (1.00) FGFR3FGFR1FGFR4FGFR2EGFR
SCHEMBL374413 0.89 FGFR3 (0.81) FGFR3FGFR1FGFR4FGFR2EGFR
SCHEMBL583166 0.85 FGFR3 (0.86) FGFR3FGFR1FGFR4FGFR2EGFR
SCHEMBL374643 0.84 FGFR3 (0.72) FGFR3FGFR1FGFR4FGFR2EGFR
SCHEMBL2017841 0.83 FGFR3 (0.84) FGFR3FGFR1FGFR4FGFR2EGFR
SCHEMBL374521 0.82 FGFR3 (0.81) FGFR3FGFR1FGFR4FGFR2EGFR
SCHEMBL17537407 0.80 SIK1 (0.81) FGFR3FGFR1FGFR4FGFR2EGFR
Infigratinib SCHEMBL374435 0.80 FGFR3 (1.00) FGFR3FGFR1FGFR4FGFR2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9783504-B2 Kinase inhibitors for the treatment of disease DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-10-10 US disclosed